Amyloid Seeds Emerge as Blood Biomarker

Plasma aggregation activity separates Alzheimer’s disease from non-Alzheimer’s dementias

1

A blood test measuring amyloid beta aggregation distinguished Alzheimer’s disease and mild cognitive impairment from normal cognition and other dementias.
2

The study involved 549 patients, including those with Alzheimer’s dementia, mild cognitive impairment, and various non-Alzheimer’s dementias.
3

The test utilized protein misfolding cyclic amplification to detect misfolded amyloid beta in plasma, with results available within 24 hours.
4

In the validation group, amyloid beta seeding activity was significantly higher in Alzheimer’s patients compared to cognitively unimpaired individuals.
5

The assay demonstrated high diagnostic performance, with area under the curve values of 0.93 for Alzheimer’s disease versus normal cognition.

1